Quidel (Nasdaq: QDEL ) is expected to report Q4 earnings on Feb. 12. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Quidel's revenues will increase 39.1% and EPS will grow 866.7%.
The average estimate for revenue is $53.4 million. On the bottom line, the average EPS estimate is $0.29.
Last quarter, Quidel tallied revenue of $33.0 million. GAAP reported sales were 0.3% lower than the prior-year quarter's $33.1 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.08. GAAP EPS were -$0.02 for Q3 against -$0.03 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 54.9%, 190 basis points worse than the prior-year quarter. Operating margin was -3.7%, 210 basis points worse than the prior-year quarter. Net margin was -2.0%, 140 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $155.3 million. The average EPS estimate is $0.46.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 166 members out of 174 rating the stock outperform, and eight members rating it underperform. Among 44 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 43 give Quidel a green thumbs-up, and one give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Quidel is outperform, with an average price target of $18.86.
Is Quidel the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.